http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-116898-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a693232b92910547c898db10feb83fef |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2019-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-116898-A1 |
| titleOfInvention | ARYLSULFONYLPIRROLCARBOXAMIDE DERIVATIVES AS ACTIVATORS OF Kv3 POTASSIUM CHANNELS |
| abstract | Compounds derived from sulfonyl- (1H) -pyrrole-3-carboxamide as activators of the Kv3 potassium channel, a pharmaceutical composition that comprises them and their use for the treatment of neurological or psychiatric disorders as well as chronic pain. Claim 1: A compound (I) of formula (1); where R¹ is selected from the group consisting of H, C₁₋₄ alkyl, C₁₋₄ fluoroalkyl, C₁₋₄ alkoxy, C₁₋₄ fluoroalkoxy, C₃₋₈ cycloalkyl, C₁₋₄ thioalkyl, C₁₋₄ thiofluoroalkyl, and halogen, particularly fluorine and chlorine; R² and R⁶ are independently selected from the group consisting of H, C₁₋₄ alkyl, C₁₋₄ alkoxy, and halogen, particularly fluorine and chlorine; R³ is selected from the group consisting of H, fluoro, and C₁₋₄ alkyl; R⁴ and R⁵ are selected from the group consisting of H and fluoro; R⁷ is selected from the group consisting of H, C₁₋₄ alkyl, halogen, such as fluorine and chlorine, C₁₋₄ alkoxy, fluoroalkyl, fluoroalkoxy, and C₁₋₄amino alkyl; Y is selected from the group consisting of oxygen and sulfur; HetAr is selected from the group consisting of 5-membered heteroaryl, 6-membered heteroaryl, and a bicyclic heteroaromatic ring system and HetAr may be substituted with one or more independently selected R⁷ substituents; when R¹ is C₁₋₄ alkoxy it can form a ring closure with R² or R⁶ when any one of these is C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.